These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6389460)

  • 1. In vitro and in vivo anti-Candida activity and toxicology of LY121019.
    Gordee RS; Zeckner DJ; Ellis LF; Thakkar AL; Howard LC
    J Antibiot (Tokyo); 1984 Sep; 37(9):1054-65. PubMed ID: 6389460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of in vitro antifungal activity of LY121019.
    Hobbs M; Perfect J; Durack D
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):77-80. PubMed ID: 3132385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species.
    Spitzer ED; Travis SJ; Kobayashi GS
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):80-1. PubMed ID: 3132386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents.
    Pfaller MA; Wey S; Gerarden T; Houston A; Wenzel RP
    Diagn Microbiol Infect Dis; 1989; 12(1):1-4. PubMed ID: 2714066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.
    Gordee RS; Zeckner DJ; Howard LC; Alborn WE; Debono M
    Ann N Y Acad Sci; 1988; 544():294-309. PubMed ID: 3063174
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.
    Khardori N; Nguyen H; Stephens LC; Kalvakuntla L; Rosenbaum B; Bodey GP
    Antimicrob Agents Chemother; 1993 Apr; 37(4):729-36. PubMed ID: 8494367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents.
    Pfaller M; Gordee R; Gerarden T; Yu M; Wenzel R
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):564-7. PubMed ID: 2504601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the antifungal activity of LY121019, a new echinocandin derivative.
    Strippoli V; D'Auria FD; Simonetti N
    Chemioterapia; 1988 Feb; 7(1):33-7. PubMed ID: 3288366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.
    Hall GS; Myles C; Pratt KJ; Washington JA
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1331-5. PubMed ID: 3058017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B.
    Meunier F; Lambert C; Van der Auwera P
    J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019.
    Pfaller MA; Gerarden T; Yu M; Wenzel RP
    Diagn Microbiol Infect Dis; 1988 Sep; 11(1):1-9. PubMed ID: 3219817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal toxicity and in vitro efficacy study of cilofungin (LY121019).
    Shahsavari M; Peyman GA; Niesman MR
    Ophthalmic Surg; 1990 Oct; 21(10):726-8. PubMed ID: 2250858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cilofungin (LY121019), a fungal cell wall synthesis inhibitor, on interactions of Candida albicans with human neutrophils.
    Meshulam T; Levitz SM; Diamond RD; Sugar AM
    J Antimicrob Chemother; 1989 Nov; 24(5):741-5. PubMed ID: 2689424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents.
    Flattery AM; Abruzzo GK; Gill CJ; Smith JG; Bartizal K
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1604-9. PubMed ID: 8807048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.
    Padula A; Chambers HF
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1822-3. PubMed ID: 2686548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B.
    Debono M; Abbott BJ; Turner JR; Howard LC; Gordee RS; Hunt AS; Barnhart M; Molloy RM; Willard KE; Fukuda D
    Ann N Y Acad Sci; 1988; 544():152-67. PubMed ID: 3063167
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.
    Bartizal K; Abruzzo G; Trainor C; Krupa D; Nollstadt K; Schmatz D; Schwartz R; Hammond M; Balkovec J; Vanmiddlesworth F
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1648-57. PubMed ID: 1416847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cilofungin (LY121019) against Candida species in vitro.
    Odds FC
    J Antimicrob Chemother; 1988 Dec; 22(6):891-7. PubMed ID: 3243737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis.
    Morrison CJ; Stevens DA
    Antimicrob Agents Chemother; 1990 May; 34(5):746-50. PubMed ID: 2193617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin.
    Fromtling RA; Abruzzo GK
    J Antibiot (Tokyo); 1989 Feb; 42(2):174-8. PubMed ID: 2647704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.